Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
Jiménez, Moraima (Hospital Universitari Vall d'Hebron)
Roldán Galvan, Elisa (Hospital Universitari Vall d'Hebron)
Fernandez-Naval, Candela (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia)
Martínez Gallo, Mónica (Hospital Universitari Vall d'Hebron)
Medina-Gil, Daniel (Vall d'Hebron Institut d'Oncologia)
Peralta-Garzón, Soraya (Vall d'Hebron Institut d'Oncologia)
Pujadas, Gemma (Vall d'Hebron Institut d'Oncologia)
Hernández, Cristina (Vall d'Hebron Institut d'Oncologia)
Pagès Geli, Carlota (Vall d'Hebron Institut d'Oncologia)
Gironella, Mercedes (Hospital Universitari Vall d'Hebron)
Fox, Maria Laura (Hospital Universitari Vall d'Hebron)
Ortí, Guillermo (Hospital Universitari Vall d'Hebron)
Barba, Pere (Hospital Universitari Vall d'Hebron)
Pumarola Suñé, Tomàs (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Cabirta, Alba (Vall d'Hebron Institut d'Oncologia)
Catalá, Eva (Vall d'Hebron Institut d'Oncologia)
Valentín, Mercedes (Vall d'Hebron Institut d'Oncologia)
Marín-Niebla, Ana (Vall d'Hebron Institut d'Oncologia)
Orfao, Alberto (Instituto de Investigación Biomédica de Salamanca)
González, Marcos (Instituto de Investigación Biomédica de Salamanca)
Campins Martí, Magda (Hospital Universitari Vall d'Hebron)
Ruiz-Camps, Isabel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Valcárcel, David (Hospital Universitari Vall d'Hebron)
Bosch Albareda, Francesc 1947- (Hospital Universitari Vall d'Hebron)
Hernández, Manuel (Hospital Universitari Vall d'Hebron)
Crespo Maull, Marta (Vall d'Hebron Institut d'Oncologia)
Esperalba, Juliana (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate both the humoral and cellular immunogenicity 1 month after the second dose of the mRNA-1273 vaccine. Antibody titers were measured by using the Elecsys and LIAISON anti-SARS-CoV-2 S assays, and T-cell response was assessed by using interferon-γ release immunoassay technology. Overall, 76. 3% (184 of 241) of patients developed humoral immunity, and the cellular response rate was 79% (184 of 233). Hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy during the previous 6 months were associated with an inferior humoral response. Conversely, age >65 years, active disease, lymphopenia, and immunosuppressive treatment of graft-versus-host disease (GVHD) were associated with an impaired cellular response. A significant dissociation between the humoral and cellular responses was observed in patients treated with anti-CD20 therapy (the humoral response was 17. 5%, whereas the cellular response was 71. 1%). In these patients, B-cell aplasia was confirmed while T-cell counts were preserved. In contrast, humoral response was observed in 77. 3% of patients undergoing immunosuppressive treatment of GVHD, whereas only 52. 4% had a cellular response. The cellular and humoral responses to the SARS-CoV-2 mRNA-1273 vaccine in patients with hematologic malignancies are highly influenced by the presence of treatments such as anti-CD20 therapy and immunosuppressive agents. This observation has implications for the further management of these patients.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Blood advances, Vol. 6 (december 2021) , p. 774-784, ISSN 2473-9537

DOI: 10.1182/bloodadvances.2021006101
PMID: 34844263

11 p, 1.3 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats